New febuxostat trial douses cardiovascular alarm
Investigators hope results from the FAST trial will lead to a rethink of boxed warnings on the drug
AusDoc brings you the latest news from the American College of Rheumatology virtual congress 2020.
Patients with gout who are treated with febuxostat are at no more increased risk of cardiovascular events or death than those taking allopurinol, European researchers have reported.
The findings from the open label FAST (Febuxostat versus Allopurinol Streamlined Trial), which contrast with previous adverse findings against the urate-lowering
